Verrica Pharmaceuticals (VRCA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Verrica Pharmaceuticals (VRCA) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.00 of bullish evidence against -0.45 bearish.

Verrica Pharmaceuticals last closed at $4.11, -1.67% on the session.

Against the IVW growth benchmark the position is -2.47% over the forecast window.

The read is built from 15 underlying insights — 0 bullish and 15 bearish.

Agreement across those insights is 100%.

20 graded predictions for VRCA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Verrica Pharmaceuticals in the 2nd percentile on return on equity, where 100 is best.

Verrica Pharmaceuticals is classified under Health Care / Pharmaceuticals, with a market capitalisation of $71.81M.

StockMap tracks Verrica Pharmaceuticals as the 107th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Verrica Pharmaceuticals ranks 125th of 151 in the group, against a group median of -0.08.